Phathom Pharmaceuticals Resubmits Erosive GERD New Drug Application To FDA
Portfolio Pulse from Benzinga Newsdesk
Phathom Pharmaceuticals has resubmitted its New Drug Application (NDA) for vonoprazan, a treatment for Erosive GERD, to the FDA. If approved, a combined U.S. commercial launch for Erosive GERD and H. pylori indications is planned for Q4 2023.
May 23, 2023 | 8:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Phathom Pharmaceuticals resubmitted its NDA for vonoprazan, a treatment for Erosive GERD. If approved, a combined U.S. commercial launch is planned for Q4 2023.
The resubmission of the NDA for vonoprazan is a positive development for Phathom Pharmaceuticals. If the FDA approves the NDA, it will allow the company to launch the drug in the U.S. market, potentially increasing its revenues and improving its market position. This news is directly related to the company and has a high importance for investors, as it could impact the company's future growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100